Kastelein Johannes Jacob Pieter's Form 4 filing
NewAmsterdam Pharma Co N.V. (NAMS) · filed Mar 9, 2026
- Accession no.
- 0001193125-26-099073
- Filed
- Mar 9, 2026
- Trade date
- Mar 5-9, 2026
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 6 non-derivative transactions and 3 derivative transactions. Open-market sales total $9.09M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Kastelein Johannes Jacob PieterCIK 0002000389 | Director, Officer (Chief Scientific Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 5, 2026 | Ordinary Shares | MOption exerciseAcquired | +104,467 | – | – | 173,769 | Indirect | |
| Mar 5, 2026 | Ordinary Shares | SSaleDisposed | −104,467 | $30.30 | −$3,165,350.1 | 69,302 | Indirect | |
| Mar 6, 2026 | Ordinary Shares | MOption exerciseAcquired | +94,124 | – | – | 163,426 | Indirect | |
| Mar 6, 2026 | Ordinary Shares | SSaleDisposed | −94,124 | $30.32 | −$2,853,839.68 | 69,302 | Indirect | |
| Mar 9, 2026 | Ordinary Shares | MOption exerciseAcquired | +101,409 | – | – | 170,711 | Indirect | |
| Mar 9, 2026 | Ordinary Shares | SSaleDisposed | −101,409 | $30.29 | −$3,071,678.61 | 69,302 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 5, 2026 | Ordinary Shares | MOption exerciseDisposed | −104,467 | $0.00 | $0 | 715,762 | Indirect | |
| Mar 6, 2026 | Ordinary Shares | MOption exerciseDisposed | −94,124 | $0.00 | $0 | 621,638 | Indirect | |
| Mar 9, 2026 | Ordinary Shares | MOption exerciseDisposed | −101,409 | $0.00 | $0 | 520,229 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.